TWINSTRAND BIOSCIENCES INC
Seattle, WA · Founded 2015 · CIK 0001677173 · Medtech · Acquired
Duplex Sequencing, an ultra-sensitive DNA sequencing technology with error correction
twinstrandbio.com →- Grants
- $13M
- 15 awards
- Sector median: 1
- Raised
- $85M
- 6 Form D · Jun 2023
- 39 months since last filing
- Contracts
- $174K
- 7 awards · Health and Human S
- #467 of 4531 in medtech
- Patents
- 25
- 3 granted · 22 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $1,938,964 | |
| Federal grant | Department of Health and Human Services · Phase II · Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | $295,409 | |
| Private capital raised | Form D · SEC | $5,280,338 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $299,790 | |
| Private capital raised | Form D · SEC | $1,177,536 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | $823,853 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | $2,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $690,175 | |
| Federal contract | Department of Health and Human Services · Duplex Sequencing Sample Analysis | $25,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Genotoxicity Assay using Duplex Sequencing | $224,797 | |
| Federal grant | Department of Health and Human Services · Phase II · Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | $954,260 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $690,175 | |
| Private capital raised | Form D · SEC | $16,301,834 | |
| Federal contract | Department of Health and Human Services · Duplex Gene Sequencing-analysis Of Six (6) Human Organoid Lung Model Samples | $9,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Early Detection of Ovarian Cancer Using Uterine Lavage and Duplex Sequencing | $221,887 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Genotoxicity Assay using Duplex Sequencing | $874,368 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $859,730 | |
| Private capital raised | Form D · SEC | $49,999,943 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Genotoxicity Assay using Duplex Sequencing | $619,680 | |
| Federal contract | Department of Health and Human Services · Duplex Sequencing Human Genotoxicity Assay For Analysis Of 12 Human Organoid Lung Model Samples | $18,000 | |
| Federal contract | Department of Health and Human Services · Sequencing Universal Kit | $24,000 | |
| Federal contract | Department of Health and Human Services · Twinstrand Biosciences, INC.:1295692 [22-006856] | $24,167 | |
| Federal contract | Department of Health and Human Services · Twinstrand Biosciences, INC.:1295692 [22-009170] | $24,000 | |
| Private capital raised | Form D · SEC | $10,278,497 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $1,139,103 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $1,139,103 | |
| Federal contract | Department of Health and Human Services · Twinstrand Duplex Sequencing Mutagenesis Kit | $49,988 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | $1,985,831 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 464 | MX3 DIAGNOSTICS, INC. | $181K | — |
| 465 | INTAN TECHNOLOGIES, LLC | $177K | — |
| 466 | ANTA BIOTECHNOLOGIES CORPORATION | $174K | — |
| 467 | TWINSTRAND BIOSCIENCES INC | $174K | $85M |
| 468 | ISCIENCE INTERVENTIONAL CORP | $174K | $24M |
| 469 | EVREN TECHNOLOGIES, INC. | $172K | — |
| 470 | SPARK BIOMEDICAL INC. | $171K | $16M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- RONNIE ANDREWSExecutive Officer
- Christopher BenoitDirector · Executive Officer
- Kellie BickelExecutive Officer
- DAVID CANNERDirector
- Elena CantExecutive Officer
- Karen DabbsExecutive Officer
- KAREN DABBSExecutive Officer
- Steve DowDirector
- Michele FernandesExecutive Officer
- Chris IgielskiDirector · Executive Officer
- Michael KrandaDirector · Executive Officer · Promoter
- Lawrence LoebDirector · Promoter
- JASON MYERSDirector
- Terry MyersonDirector
- Michael PelliniDirector
- MIKE PELLINIDirector
- Linden RhoadsDirector
- Jesse SalkDirector · Executive Officer · Promoter
- Michael SchmittDirector · Promoter
- Soma SomasegarDirector
- SOMA SOMASEGARDirector
- Chad WaiteDirector · Executive Officer
- CHAD WAITEDirector
- Chad Waite, Jr.Director · Executive Officer
Patents
- Methods And Reagents For Characterizing Genomic Editing, Clonal Expansion, And Associated Applicationsgranted
- Genomics Alignment Probability Score Rescalerapplication
- Adapters, Methods, And Compositions For Duplex Sequencingapplication
- Methods And Reagents For Enrichment Of Nucleic Acid Material For Sequencing Applications And Other Nucleic Acid Material Interrogationsapplication
- Methods And Reagents For Resolving Nucleic Acid Mixtures And Mixed Cell Populations And Associated Applicationsapplication
- Reagents And Adapters For Nucleic Acid Sequencing And Methods For Making Such Reagents And Adaptersapplication
- Methods And Reagents For Characterizing Genomic Editing, Clonal Expansion, And Associated Applicationsgranted
- Reagents And Adapters For Nucleic Acid Sequencing And Methods For Making Such Reagents And Adaptersgranted
- Adapters, Methods, And Compositions For Duplex Sequencingapplication
- Methods And Reagents For Nucleic Acid Sequencing And Associated Applicationsapplication
- Methods And Reagents For Efficient Genotyping Of Large Numbers Of Samples Via Poolingapplication
- Methods And Reagents For Detecting And Assessing Genotoxicityapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.